Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

$10.2 million in operating activities in the year ended May 31, 2008 compared with $6.3 million during the year ended May 31, 2007 reflecting the increase in research and development activities during the year. At May 31, 2008, Lorus had cash and cash equivalents, short-term investments and marketable securities of $9.4 million compared to $12.2 million at May 31, 2007. Lorus believes that its current cash and cash equivalents, short-term investments and marketable securities and interest income will be sufficient to carry out the current research and development plans and operations through to the first quarter of fiscal 2010.

Lorus Therapeutics Inc.

Consolidated Statements of Loss

Years Ended May 31

-------------------------------------

(Canadian dollars) 2008 2007 2006

-------------------------------------------------------------------------

REVENUE $ 133 $ 107 $ 26

-------------------------------------------------------------------------

EXPENSES

Cost of sales 2 16 3

Research and development 6,087 3,384 10,237

General and administrative 3,888 3,848 4,334

Stock-based compensation 719 503 1,205

Depreciation and amortization of

fixed assets 317 402 771

-------------------------------------------------------------------------

Operating expenses 11,013 8,153 16,550

Interest expense on convertible

debentures 1,029 1,050 882

Accretion in carrying value of

convertible debentures 1,045
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership ... production from bioactive small molecules. Based on ... enables convenient and timely assessment of critical metabolite ... President of Commercial Operations, Christian Darabant, “the value ... can be measured directly by comparison with the ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
Breaking Biology Technology:Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... , ... Centage extends its financial performance management offerings to bring powerful, dynamic, driver-based planning, ... ... 2009 -- Centage Corporation, a leading provider of integrated budgeting, forecasting, consolidation and ...
... BOZEN, Italy, August 10 , ... Health Robotics today announced that it ... Robotics, CytoCare Robot. The,agreement enables McKesson to achieve its goal ... admixtures. , "We are very pleased ...
... LEXINGTON, Mass. and HEIDELBERG, Germany, Aug. 10 ... DNA-capture method, HybSelect(TM), to re-sequence the exons of genes involved ... the ultimate goal of developing genetic tests to detect carrier ... , In this collaboration the NCGR will bring ...
Cached Biology Technology:Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid-Market Enterprises 2Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid-Market Enterprises 3McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 2The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 3
(Date:8/20/2014)... Women who are poor experience higher cortisol levels in ... of the stress hormone, putting them at greater ... a new research from the University of Colorado Denver. ... American Journal of Human Biology , is the first ... to the socioeconomic status of their mothers during pregnancy. ...
(Date:8/20/2014)... When a colony of honeybees grows to about 4,000 ... reproductive cycle: the building of a special type of ... team of experts from the Department of Neurobiology and ... what starts the reproductive cycle of honeybee colonies. The ... The Science of Nature . , Reproduction isn,t ...
(Date:8/20/2014)... leaves, photosystem 1 (PS1) absorbs light and its ... carbon dioxide to biomass. Photovoltaic devices, mostly build ... but produce electricity. One approach for the development ... the semi-conductor with the isolated membrane protein complexes ... a highly stable PS1 from thermophilic cyanobacteria that ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Worker bees 'know' when to invest in their reproductive future 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... ) continues to expand at a record pace with the ... 2012, EOL provides data on nearly half of all described ... issues from the International Union for the Conservation of Nature ... before. In the four years since its first ...
... of species previously unknown to science have been discovered ... dark environment surrounding hydrothermal vents. The discoveries, made ... of Southampton and British Antarctic Survey, include new species ... an octopus. For the first time, researchers have ...
... Jan. 3, 2011 By manipulating the way bacteria ... have achieved an unprecedented degree of control over the ... potentially significant health and industrial applications, particularly to bioreactor ... Professor Thomas K. Wood and Associate Professor Arul Jayaraman ...
Cached Biology News:The Encyclopedia of Life expanding at a record pace 2'Lost world' discovered around Antarctic vents 2Manipulating way bacteria 'talk' could have practical applications, Texas A&M profs say 2Manipulating way bacteria 'talk' could have practical applications, Texas A&M profs say 3